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INTRODUCTION
According tothe central dogmaofbiol-
ogy,ribonucleic acids (RNA)' were thought
to play the role of messengers (mRNA)
that are mere intermediates between DNA
and proteins. Recent advances in under-
standing the capabilities of RNA have
proven this wrong.
The catalytic reaction required for
making proteins is carried out by RNA [1].
RNA evolved in vitro can bind small mol-
ecules with high specificity [2]. Cellular
mRNAs can control gene expression
directly in response to metabolites [3, 4].
The aforementioned studies and many others
have proven that RNA exhibits all the
properties of proteins that are key players
in practically every cellular process. This
realization has provided impetus to thera-
peutic approaches that use RNA to correct
disease states [5].
The object of this review is to intro-
duce one such exciting possibility for ther-
apeutic intervention: the use of RNA
enzymes (ribozymes). The progress in this
field will be summarized, and some of the
obstacles that need to be overcome will be
evaluated.
EARLY DAYS OF CATALYTIC RNA
Ribozymes are RNAs that catalyze a
chemical reaction, e.g., cleavage ofa cova-
lent bond (reviewed in [6] and [7]). Cech
and coworkers first described RNA self-
splicing in their studies of the 413-
nucleotide group I intron from Tetrahymena
thermophila [8]. Several years later, Zaug
and colleagues described a variant ofthe T.
thermophila ribozyme that could act in
trans (i.e., as a sequence specific endori-
bonuclease acting upon other RNA sub-
strates; [9]). The work of Forster and
Symons [10, 11] on plant virusoid RNAs
suggested smaller RNA domains were
capable of ribozyme activity. Uhlenbeck
was the first to demonstrate a small active
ribozyme, the hammerhead ribozyme, in
which the catalytic and substrate strands
were separated [12]. Such ribozymes bind
substrate RNAs through base-pairing inter-
actions, cleave the bound target RNA,
release the cleavage products, and are recy-
cled so that they can repeat this process
multiple times. Haseloff and Gerlach enu-
merated general design rules for simple
hammerhead ribozymes capable of acting
in trans [13]. Armed with these simple
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rules,ribozyme engineers were ready to inter-
vene with gene function in vivo. One ofthe
earliest studies on the in vivo efficacy of
hammerhead ribozymes showed a60 percent
reduction in specific gene expression in mon-
key cells [14]. In order to make ribozyme
therapy viable, further study was required.
IN VITRO AND CELLULAR STUDIES
To have a ribozyme that is effective in
vivo,extensive in vitro and cell culture stud-
ies are needed. The understanding gleaned
from these studies is then used to obtain
physiologically acting ribozymes with good
pharmaco-kinetic properties. Below are
some of the important considerations for
such in vitro and cell culture studies.
Ribozyme kinetics
Ribozymes appear to obey simple
Michaelis-Menton type kinetics [12, 15].
Under saturating conditions, cleavage rates
are determined by the ribozyme Kcat/Km*
The most efficient wild type ribozymes
display Kcat/Km values of 108 M-' min-I
(about the order ofthe apparent hybridiza-
tion rate constant for two oligonucleotides
[6]). It has been suggested that within the
intracellular environment, the hybridiza-
tion step may berate limiting fortrans-acting
ribozymes [16]. Kinetic and mutagenesis
experiments have indicated that for both
natural and engineered ribozymes, at sub-
strate saturation, product release may be
rate limiting [16, 17]. This release rate-
limitation is due to the length of the
sequence of RNA to which the ribozyme
hybridizes. Therefore, studies have been
carried out to optimize the length of the
hybridizing armsofaribozyme [e.g., 17, 18].
Analysis ofribozyme activity
Demonstration ofribozyme activity in
vitro isrelatively straight-forward: incubation
oftheribozyme and its substrate followed by
polyacrylamnide gel electrophoresis analysis,
allows detection of the cleavage products.
Studying ribozyme activity in cells is more
complex. First, it requires a means of
delivering the ribozymes into the cell. This
is usually accomplished in one of three
ways: delivery ofpre-formed ribozymes by
microinjection or by cationic liposomes;
delivery by transfection with plasmid con-
structs designed to express the ribozyme
RNA; ordelivery by infection with a retro-
viral vector bearing the ribozyme. Second,
cleavage products produced by the ribozyme
usually cannot be detected within cells,
possibly due to the activity of intracellular
ribonucleases that quickly degrade the
cleaved substrate RNA [14, 19].Therefore,
indirect evidence is usually presented from
which ribozyme activity is inferred.
RIBOZYMES IN CLINICALTRIALS
Several phase I and II clinical trials
have been initiated using trans-cleaving
ribozymes on patients with infectious dis-
eases or cancer. In these studies, the
ribozymes have been delivered to the
patients either by gene therapy methods or
by direct injection ofa synthetic ribozyme.
Ribozymes deliveredusinggene therapy
methods
The gene-therapy-based trials have
focused upon developing ribozyme-based
treatments for individuals infected with
human immunodeficiency virus (HIV).
Three separate groups have used retroviral
vectors to introduce expression cassettes
for anti-HIV ribozymes into CD4+ lym-
phocytes or CD34+ haematopoietic pre-
cursors ex vivo that have been taken from
the infected patient or from an identical twin
[20-22]. The transduced cells are then
infused into the patient, and the engraft-
ment and survival ofthe ribozyme contain-
ing cells are monitored. Initial results from
these studies suggest that transfer of
ribozyme-encoding genes to HIV-infected
individuals is well tolerated, and trans-
duced cells can persist in the patient [21].Jose: Ribozyme therapy 217
Moreover, preliminary reports suggest that
anti-HIV ribozyme-containing cells may
possess a transient survival advantage in
the patient compared with cells transduced
with a control vector [21]. Larger clinical
trials must now be performed to evaluate
the efficacy ofanti-HIV ribozymes. Critical
factors that will influence the success of
such trials will be the development of
gene-transfer systems that can efficiently
transduce pluripotent haematopoietic stem
cells and the generation of improved
ribozyme expression cassettes that can
increase the survival advantage of trans-
duced cells.
Synthetic ribozymes delivered using
direct injection
Three different nuclease-resistant syn-
thetic ribozymes are being evaluated in
clinical trials [23]. Each ofthese trials uses
a hammerhead ribozyme derivative that
contains chemical modifications that greatly
enhance the ribozyme's stability in biolog-
ical fluids [24]. Moreover, methods have
been developed that enable large-scale
synthesis of this new class of therapeutic
agents under good manufacturing practice
protocols [25]. All three of these synthetic
ribozymes target RNAs whose expression
is associated with the induction orprogres-
sion of cancer, and all three have shown
promising results in pre-clinical cell and
animal experiments [26, 27]. In 1998, the
first of these ribozymes entered a phase I
trial targetingflt-] mRNA, which encodes
the high affinity receptor for the angio-
genic protein vascular endothelial growth
factor (VEGF). Results from this and two
subsequent phase I trials show that daily
intravenous or subcutaneous delivery of
this compound is well tolerated and that
plasma levels could be maintained for pro-
longed periods after subcutaneous delivery
[23]. Currently its therapeutic efficacy is
being evaluated in phase II clinical trials
for breast and colorectal cancer. The other
two synthetic ribozymes to enter clinical
trials target mRNA of human epidermal
growth factor receptor type 2, which is
overexpressed in many breast cancers, and
hepatitis C virus (HCV) RNA which is
associated with liver cirrhosis and hepato-
cellularcarcinoma. Results fromthese initial
efficacy studies will provide the first sig-
nificant into the long-term utility of trans-
cleaving ribozymes as therapeutic agents.
The clinical factors that will most likely
determine the success of these synthetic
ribozyme efficacy trials are the ability to
deliver ribozymes efficiently into the
appropriate cell in vitro, and the level and
duration of target-gene inhibition that is
required to alter disease pathology or slow
disease progression.
OBSTACLES FACING IN VIVO
APPLICATION OF RIBOZYMES
Ribozymes must hybridize to RNA
targets that possess their own secondary
structure, a feature of the target known to
affect the efficacy ofribozymes [28]. Com-
puter folding programs for RNA may help
determine regions of RNA likely to be
involved in RNA structure or help predict
the activity ofribozymes [29, 30]. However,
these algorithms have noteliminated emper-
ical approaches since the algorithms achieve
an 80 percent accuracy at best [31, 32].
Targeting of the ribozyme by anchor
sequences able to hybridize to the RNA at
sites distant from the actual cleavage site
may provide an altemate strategy forcircum-
venting secondary structure at the ribozyme
cleavage site [33].
The efficacy of a ribozyme depends
strongly on the persistence of the affects
causedby it in vivo. None ofthe modalities
proposed to date can eliminate the disease/
target. Forribozymes to benefit individuals
with chronic disorders such as cancer and
HCV (or HIV) infection, long-term, high-
level inhibition of the target transcripts
will probably be required. This may be dif-218 Jose: Ribozyme therapy
ficult to achieve in practice, especially
when targeting highly expressed viral RNAs.
Another critical determinant of the
efficacy of a ribozyme in a physiological
setting is the ability to deliver the
ribozyme to the sub-cellular compartment
that has the target RNA. Ifthe target is out-
side the vascular system, the agent will
have to extravasate. Non-gene nucleic acid
drugs have molecular weights in the 3-10
kDa range, so extravasation is not a partic-
ular problem for the agent itself. However,
as these drugs do not permeate into the
cytoplasm of cells but are found primarily
in the endosome compartment [34, 35],
they will most likely require some covalent
modification or delivery system to mediate
their efficient entry into the cytoplasm of
the target cells [36].
NEXT GENERATION RIBOZYMES:
FINE CONTROL OF ACTIVITY
RNA catalysis can be modulated
allosterically just as finely as protein catal-
ysis [37]. These allosteric ribozymes are
activated or inactivated by small metabo-
lites. The recent findings on the use ofsuch
modulation by cellular mRNAs to control
gene expression [3, 4], raises the possibili-
ty of allosterically activated therapeutic
ribozymes. This would increase the level of
control that one has over the therapy. For
example, if an allosteric ribozyme were
delivered using gene therapy approaches,
then it can be specifically activated only
when needed by administering a small
molecule (the "metabolite"). This approach
thus provides both temporal and dosage
control. Furthermore, RNA is capable of
binding its metabolites cooperatively [38].
Incorporating a series of domains in the
design of an allosteric ribozyme allows for
it to be activated only when two or more
metabolites were present at the same time.
This provides a mechanism to increase
specificity of ribozyme action.
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